Focused Ultrasound Foundation and Cancer Research Institute Partner to Advance Cancer Immunotherapy – Newswise (press release)
|
Focused Ultrasound Foundation and Cancer Research Institute Partner to Advance Cancer Immunotherapy
Newswise (press release) Newswise — Charlottesville, VA, and New York, NY – June 22, 2017 – The Focused Ultrasound Foundation (FUSF) and the Cancer Research Institute (CRI) are establishing a partnership with the goal of advancing the development of new focused ultrasound … |
|
French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy
Labiotech.eu (blog) Noble Généthon has teamed up with ignominious Sarepta to develop a gene therapy for the Duchenne variety of the muscle wasting disease. Dedicated to rare diseases since 1990 and more recently to gene therapy, Généthon is one of very few not-for-profit … |
|
French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy
Labiotech.eu (blog) Noble Généthon has teamed up with ignominious Sarepta to develop a gene therapy for the Duchenne variety of the muscle wasting disease. Dedicated to rare diseases since 1990 and more recently to gene therapy, Généthon is one of very few not-for-profit … |
|
French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy
Labiotech.eu (blog) Noble Généthon has teamed up with ignominious Sarepta to develop a gene therapy for the Duchenne variety of the muscle wasting disease. Dedicated to rare diseases since 1990 and more recently to gene therapy, Généthon is one of very few not-for-profit … |
|
Sweden Launches Initiative to Establish Center for Cell and Gene Therapy Research
Genetic Engineering & Biotechnology News Swedish regenerative medicine firm Xintela, has been appointed a partner in the 6-year project to establish the CAMP cell and gene therapy research centre, with SEK 48 million ($5.5 million) in funding from the country’s innovation agency and research … |
Xconomy |
Repare Raises $68M in Series A to Develop CRISPR-Based Synthetic Lethality Platform
Genetic Engineering & Biotechnology News (blog) Versant Venture and MPM Capital co-led a $68-million Series A fundraising round to establish Repare Therapeutics, a Canada-based cancer drug company exploiting a high-throughput, CRISPR-based screening platform to identify synthetic lethality cancer … Celgene-backed cancer biotech Repare emerges from stealth with $68MFierceBiotech Repare Nabs $68M To Find Synthetic Lethal Cancer Targets Beyond PARPXconomy Repare Therapeutics Raises US$68 Million Series ABusiness Wire (press release) |